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Abstract 
Background: Prospective randomized controlled studies have demonstrated that addition of chlorhexidine (CHG) 
dressings reduces the rate of catheter (central venous and arterial)‑associated bloodstream infections (CABSIs). How‑
ever, studies confirming their impact in a real‑world setting are lacking.
Methods: We conducted a real‑world data study evaluating the impact of incrementally introducing chlorhexidine 
dressings (sponge or gel) in addition to an ongoing catheter bundle on the rates of CABSI, expressed as incidence 
density rates per 1000 catheter‑days measured as part of a surveillance program. Poisson regression models were 
used to compare infection rates over time. Both dressings were used simultaneously during one of the five study 
periods.
Results: From 2006 to 2014, 18,286 patients were admitted (91,292 ICU‑days and 155,242 catheter‑days). We 
recorded 111 CABSIs. We observed a progressive but significant decrease of CABSI rates from 1.48 (95% CI 1.09–2.01) 
without CHG dressings to 0.69 (95% CI 0.43–1.09) and 0.23 (95% CI 0.11–0.48) episodes per 1000 catheter‑days when 
CHG sponge and CHG gel dressings were used (p = 0.0007; p < 0.001). A non‑significant lower rate of infections 
occurred with CHG gel compared with CHG sponge dressings. An identical low rate of allergic skin reactions (0.3/1000 
device‑days) was observed with both types of CHX dressings. Post‑study data until 2018 confirmed a sustained 
decrease of infection rates over 11 years.
Conclusions: The addition of chlorhexidine dressings to all CVC and arterial lines to an ongoing catheter bundle was 
associated with a sustained 11‑year reduction of all catheter‑associated bloodstream infections. This large real‑world 
data study further supports the current recommendations for the systematic use of CHG dressings on all catheters of 
ICU patients.
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Introduction
Despite the successful widespread implementation of 
catheter bundles, central line-associated bloodstream 
infections remain an important cause of preventable 
nosocomial infections in patients requiring intensive 
care unit (ICU) management [1–4]. The multimodal 
strategies included in these bundles (i.e., standardiza-
tion of procedures and care, skin preparation, hand 
hygiene, aseptic techniques and maximal barrier pre-
caution for insertion) successfully addressed most 
recognized risk factors for catheter infections [5, 6]. 
However, the efficacy of these recommended bundles 
seems to plateau around 1.0 episode per 1000 cathe-
ter-days [7–11]. This translates into the persistence of 
a significant number of preventable catheter-related 
infections in high-volume ICUs complying with the 
benchmark [12–14].
By controlling bacterial load at the site of insertion, 
dressings continuously releasing chlorhexidine gluco-
nate (CHG) decreased the rate of central line-associ-
ated infections in two large prospective multicenter 
randomized trials among critically ill patients [15, 
16]. These results were confirmed by a meta-analysis 
including nine randomized controlled trials compar-
ing either CHG sponge or CHG gel dressings (55,915 
catheter-days) with regular dressings (54,583 catheter-
days) [17].
Based on these studies, recommendations for the use 
of CHG dressings have been included in the CDC and 
NHS guidelines [18, 19]. However, studies confirming 
the effectiveness of these antiseptic-containing dress-
ings in a real-world setting are still lacking. Moreo-
ver, the two types of CHG dressings have never been 
directly compared.
We took advantage of a prospective bloodstream 
infection surveillance program for an ongoing catheter 
bundle to evaluate the impact of the progressive intro-
duction of two types of CHG dressings on all arte-
rial and central venous catheters inserted in patients 
admitted to a large mixed ICU over a 13-year period. 
For the first 2  years we collected baseline data, and 
during the following 7 years, we introduced the CHG 
dressings in four different steps. The objectives of the 
study were to assess whether the progressive introduc-
tion of CHG dressings to an ongoing catheter bundle 
could further reduce the rate of catheter-associated 
bloodstream infections and to compare the effective-
ness of two different types of CHG dressing (CHG 
sponge + transparent dressing versus CHG gel all-in-
one dressing) on the rate of catheter-associated blood-
stream infection.
Methods
Design
This is a real-word data study to evaluate the impact of 
CHG dressings in addition to an already ongoing cath-
eter bundle on the incidence density rate of catheter-
associated bloodstream infections (CABSIs).
Setting
A 35-bed mixed adult ICU of the Centre Hospitalier 
Universitaire Vaudois (CHUV), Lausanne, Switzer-
land, a primary and referral hospital for a population 
of 250,000 and 1,500,000, respectively. This is the only 
adult ICU in the hospital and consists of five distinct 
units. Allocation of patients is determined by bed avail-
ability and not by a patient’s specific conditions.
Participants
All consecutive adult patients admitted to the ICU 
from January 2006 to December 2018 were included. 
Burn and ECMO patients were excluded from the anal-
ysis, as the enhanced bundle could not be systemati-
cally applied.
Ethics
As the interventions were included in the measures tar-
geted at improvement of the quality of care, with prod-
ucts with a patent for use in patients in Switzerland, the 
commission cantonale d’éthique de la recherche sur l’être 
humain and the institutional review board approved 
the study and waived the need for informed consent.
Data extraction
As part of the routine and mandatory data collection to 
comply with the “minimal data set” of the Swiss Soci-
ety of Intensive Care Medicine, demographic data and 
SAPS II scores were collected [20]. ICU and hospital 
length of stay and mortality were prospectively col-
lected for each patient. Comorbidities were defined 
using definitions of the SAPS II score.
Take‑home message 
The addition of chlorhexidine dressings to all CVC and arterial lines to an 
ongoing catheter bundle to all patients consecutively admitted to a 
large mixed ICU resulted in a significantly sustained 11‑year reduction 
of all catheter‑associated bloodstream infections
This large real‑world data study further supports the current recommen‑
dations for the systematic use of CHG dressings on all catheters of ICU 
patients
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Intervention
The intervention consisted of four stepwise modifica-
tions to an already established catheter bundle with 
progressive introduction of CHG dressings from 2007 
to 2014 (Suppl Table 1).
Comparator (baseline): period A (January 2006–October 
2007)
The standard of care as of January 2006 consisted of the 
following catheter bundle (Supplemental Table  2): (1) 
general infection control measures (hand hygiene, stand-
ard and isolation precautions); (2) guidelines for catheter 
insertion (checklist for material preparation, standard-
ized hair removal with clippers and CHG-based skin 
antisepsis, maximal sterile barrier precaution); (3) han-
dling (avoidance of needle and needleless connectors, 
systematic CHG disinfection of stop-cocks with new caps 
each time the hub is accessed); (4) maintenance (daily 
check for catheter necessity, signs of catheter infection, 
dressing integrity and need for replacement). To guaran-
tee uniform application of the bundle, a designated phy-
sician and a designated nurse led the entire bundle and 
gave periodic feedback based on surveillance data [1, 7]. 
The designated clinical nurse specialist systematically 
trained ICU nurses on all elements of the bundle, includ-
ing daily assessment of the dressings and face-to-face 
feedback and coaching. The designated physician sys-
tematically trained ICU physicians on how to apply the 
guidelines for insertion. This bundle was applied to all 
arterial and central venous lines [21].
Stepwise interventions: periods B through E and post‑study 
period
To guarantee uniform implementation of the stepwise 
interventions (Supplemental Table 1), the dedicated clini-
cal nurse specialist updated the institutional protocol, 
highlighted the changes specifically related to the use of 
the CHG dressings before each period, systematically 
trained ICU nurses to use these updated practices and 
completed a daily assessment of the CHG dressings with 
face-to-face feedback and coaching.
Period B—November 2007–Nov 2009
CHG sponge + transparent dressing on jugular and 
femoral CVC in all units.
Period C—December 2009–May 2011
CHG sponge + transparent dressing on all CVC and 
arterial catheters in all units.
Period D—June 2011–May 2013
CHG sponge + transparent dressing in three units (18 
beds) and CHG gel all-in-one dressing in two units (14 
beds) on all CVC and arterial catheters.
Period E—June 2013–December 2014
CHG gel all-in-one dressing in all units on all CVC and 
arterial lines.
Post-study period—January 2015–December 2018
CHG gel all-in-one dressing in all units on all CVC and 
arterial lines.
Materials
  • CHG sponge dressing  (Biopatch®, Ethicon Inc., 
Somerville, NJ) covered by a transparent dressing 
(3M™ Tegaderm™ without disinfectant, 3  M, Saint 
Paul, MN)
  • CHG gel all-in-one dressing, containing CHG in a gel 
directly embedded within the transparent dressing 
(3  M™ Tegaderm™ CHG Chlorhexidine Gluconate 
I.V. Securement Dressing, 3 M, Saint Paul, MN).
Outcomes
Primary outcome
Number of catheter-associated bloodstream infections 
(CABSIs) per 1000 catheter-days over each study period. 
Catheter-associated bloodstream infections were defined 
as either catheter-related infection or a primary bacte-
remia (Fig.  1). Secondary bloodstream infections were 
explicitly excluded [18].
Secondary outcomes
  • Number of catheter-associated bloodstream infec-
tions per 1000 catheter-days by type of dressing and 
by type of catheter (CVC versus arterial).
  • Numbers of catheter-related bloodstream infections 
(CRBSI) and primary bacteremia over each study 
period, by type of dressing and by type of catheter 
(CVC versus arterial).
Measurements
Measurement of catheter‑associated bloodstream infections
A computer-based institutional surveillance program 
automatically identified every episode of positive blood 
culture linked to patients having stayed or actually stay-
ing in the ICU.
The hospital infection control staff reviewed each epi-
sode quarterly with the dedicated ICU physician. First, 
each episode was attributed to one the following catego-
ries: (1) community acquired (< 48  h of hospital admis-
sion), (2) hospital non-ICU acquired (< 48  h of ICU 
admission) and (3) hospital ICU acquired. Second, both 
community-acquired and hospital ICU-acquired posi-
tive blood cultures were further adjudicated to four cat-
egories: (1) catheter-related bloodstream infection, (2) 
primary bacteremia, (3) secondary bacteremia and (4) 
contamination [18].
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Measurement of catheter‑days
For each patient, the time of insertion of the catheter, 
time of its removal and catheter type (arterial-venous) 
were recorded in the computerized information system 
(Metavision, iMDsoft® Ltd., Tel Aviv Israel). For patients 
admitted with a catheter already inserted, the time of 
Fig. 1 Definitions of infections. There are two different scenarios. Scenario 1: patient is admitted directly from outside of the hospital. In these cases, 
any episode of bloodstream infection was attributed to the ICU. Scenario 2: Patient is admitted from within the hospital. In this case, the episode of 
infection is attributed to the ICU only when it occurs ≥ 48 h from admission
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insertion was set as the time of patient ICU admission. 
Similarly, for patients discharged with a catheter in place, 
the time of discharge was set as equivalent to the time of 
catheter removal.
ICU catheter-days were computed as the sum of the 
catheter time duration (removal time minus insertion 
time) for every central venous catheter (including dialysis 
catheters and introducers sheaths for pulmonary artery 
catheter) and arterial catheters.
A new version of the computerized information system 
was implemented in January 2015. While this new ver-
sion allows for a simplified computation of overall CVC-
days, it precludes the analysis of data at the individual 
patient level. Meanwhile, other surveillance methods 
remain the same.
Statistics
Demographics and patients characteristics
Continuous variables are reported as the mean and 
standard deviation (SD) or as medians and interquartile 
ranges [IQR]. Categorical variables are reported as fre-
quencies and percentages.
Incidence density rates over the study periods
The numbers of CABSI, CRBSI and primary bacteremia 
events per 1000 catheter-days over the different periods 
were reported as incidence density rates (and their 95% 
CI). The incidence density rates were tested using a Pois-
son regression model (SAS 9.3 PROC GENMOD). The 
log of the catheter-days was used as the offset, and the 
dispersion parameter was estimated to help determine 
whether over-dispersion needed to be accounted for in 
the Poisson model. Each period was compared with the 
baseline and the preceding one. In addition, period C, 
where only CHG sponge was used, was compared with 
period E, where only CHG gel was used. Multiple com-
parisons for the three measures of CABSI, CRBSI and 
primary bacteria were done using a Bonferroni correc-
tion (p < 0.05 ÷ 3 = 0.017 was considered significant). 
Comparisons to period A were done using Dunnett’s 
method.
During period D, CHG gel dressings were introduced 
in two units (14 beds), whereas CHG sponge dressings 
were maintained in the three other units (18 beds). This 
allowed for a contemporaneous comparison of the effect 
of both dressings using CABSI, CRBSI and primary bac-
teremia as outcomes. The comparisons were carried out 
using the same Poisson regression model.
Sensitivity analysis
Individual data and catheter-days were gathered from 
each individual ICU stay (n = 19,423) including the 111 
CABSIs (70 CRBSIs and 41 primary bacteremia events). 
We used a Cox proportional hazards regression model 
(SAS 9.3 PROC PHREG), with catheter-days representing 
the time factor and CABSI as the event of interest. Mod-
els were adjusted on age at ICU entry, SAPS 2 and dura-
tion of mechanical ventilation.
Results
Characteristics of patients and risk factors for CABSI
From January 2006 to December 2014, 18,286 patients 
were admitted to the medico-surgical ICU accounting 
for 91,292 treatment-days and 155,242 catheter-days con-
sisting of 68,823 arterial and 89,419 central venous cath-
eter-days. Most admissions were unscheduled (> 70%), 
and 67% occurred after surgery (Table 1). Over time, the 
average age of patients went up; they were more severely 
affected (SAPS II) and required more organ failure sup-
port therapies such as mechanical ventilation or renal 
placement therapy. We observed an increase in catheter-
days, case mix severity, workload as well as ICU and hos-
pital mortalities over the study periods.
Incidence density rates of CABSI
Over the 9 years of observation, 111 CABSIs were diag-
nosed, including 70 CRBSI and 41 primary bacteremia 
cases  (Supplemental Fig.  1). The stepwise introduction 
of various CHG dressings over the 9  years (supplemen-
tal Table  1) in addition to the ongoing catheter bundle 
(supplemental Table  2) progressively and significantly 
reduced CABSIs. Incidence density rates decreased from 
1.48 (95% CI 1.09–2.01) episodes per 1000 catheter-days 
in period A when no CHG dressings were used to 0.23 
(95% CI 0.11–0.48, p < 0.001) episodes per 1000 catheter-
days in period E when CHG gel dressings were used for 
all patients. Looking at the individual components of 
CABSI, the decrease in CRBSI from 1.12 (95% CI 0.79–
1.59) to 0.10 (95% CI 0.03–0.31, p < 0.001) was statisti-
cally significant, but the decrease in primary bacteremia 
from 0.36 (95% CI 0.19–0.67) to 0.13 (95% CI 0.05–0.35, 
p = 0.059) was not (Supplemental Fig. 2).
Sensitivity analysis
We performed a sensitivity analysis at the patient level 
to determine whether the variation in the case mix over 
the periods might have contributed to the observed 
reduction of the CABSI, CRBSI and primary bactere-
mia rates. After adjusting for age at ICU entry, SAPS 2 
and duration of mechanical ventilation, the periods of 
bundle exposure still remained significant (p < 0.0001, 
p < 0.0001 and p = 0.013), with periods D and E show-
ing significantly lower CABSI rates than period A (base-
line) (p < 0.0001, p < 0.0001 and p = 0.035), period B 
(p < 0.0001, p = 0.0011 and p = 0.014, respectively) and 
period C (p = 0.0006, p = 0.0024 and p = 0.014). There 
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Table 1 Characteristics of ICU activities and patients by study period
Period A B C D E
All January 2006 
to October 
2007
November 2007 to 
November 2009
December 2009 to 
May 2011
June 2011 to May 2013 June 2013 to 
December 
2014
Type of disinfectant 
dressing added to 
the ongoing catheter 
bundle*
None CHG sponge on CVC 
only
CHG sponge on all 
catheters
Replacement of CHG 
sponge by CHG gel 
in 2 out of 5 ICUs
CHG gel on 
all catheters 
(five of five 
ICUs)
ICU activity
 ICU treatment days 91,292 17,185 20,429 15,476 20,726 17,476
 Mean ICU LOS, days 
(SD)
5.0 (15.6) 4.3 (7.5) 4.4 (7.9) 5.1 (9.2) 5.3 (11.6) 6.3 (17.3)
 Admissions (all ICU 
stays), n
19,423 4213 4931 3213 4133 2933
 Emergency (%) 13,651 (70.3) 3037 (72.1) 3484 (71.5) 2183 (70.1) 2872 (71.3) 2075 (70.7)
 Surgical admissions, 
n (%)
13,018 (67.0) 2779 (66.0) 3258 (66.1) 2265 (70.5) 2749 (66.5) 1967 (67.1)
 Scheduled surgery, 
n (%)
5722 (29.5) 1222 (29.0) 1409 (28.6) 963 (30.0) 1211 (29.3) 917 (31.3)
 Emergency surgery, 
n (%)
7296 (37.5) 1557 (37.0) 1849 (37.5) 1302 (40.5) 1538 (37.2) 1050 (35.8)
Site of surgery
 Cardiovascular, n (%) 2131 (16.4) 436 (15.7) 536 (16.5) 343 (15.1) 452 (16.4) 364 (18.5)
 Digestive, n (%) 1621 (12.5) 296 (10.7) 432 (13.3) 268 (11.8) 356 (13.0) 269 (13.7)
 Neurosurgery, n (%) 1173 (9.0) 300 (10.8) 313 (9.6) 203 (9.0) 204 (7.4) 153 (7.8)
 Thoracic, n (%) 663 (5.1) 138 (5.0) 163 (5.0) 106 (4.7) 132 (4.8) 124 (6.3)
 Trauma, n (%) 795 (5.9) 174 (6.3) 194 (6.0) 137 (6.1) 145 (5.3) 145 (7.4)
 Workload: NEMS 
mean (SD) per 12 h 
shift
30 (25–37) 28 (27–32) 31 (27–37) 31 (27–37) 30 (25–37) 29 (22–36)
ICU treatments
 Patients with ventila‑
tion, admissions (%)
7146 (36.8) 1306 (30.1) 1533 (31.1) 1216 (37.9) 1492 (36.1) 1599 (54.5)
 Ventilation‑days 50,852 8008 10,901 9445 12,574 9924
 Mechanical ventila‑
tion, mean days/
months (SD)
471 (108) 364 (76) 436 (80) 525 (77) 524 (116) 522 (79)
 Catheter‑days 155,242 27,713 34,363 26,128 36,689 30,349
 CVC (%) 89,489 (57.6) 15,547 (56.1) 19,553 (56.9) 15,024 (57.5) 21,641 (59.0) 17,724 (58.4)
 CVC‑jugular (%) 41,684 (46.6) 6618 (42.6) 8365 (42.8) 7128 (47.4) 10,642 (49.2) 8931 (50.4)
 CVC‑sub‑clavian (%) 16,747 (18.7) 3549 (22.8) 3740 (19.1) 3070 (20.4) 3866 (17.9) 2521 (14.2)
 CVC‑femoral (%) 31,058 (34.7) 5380 (34.6) 7448 (38.1) 4826 (32.1) 7132 (33.0) 6272 (35.4)
 Arterial (%) 65,753 (42.3) 12,166 (43.9) 14,810 (43.1) 11,104 (42.5) 15,048 (41.0) 12,625 (41.6)
 Catheter‑days per 
month, mean (SD)
1419 (275) 1161 (189) 1322 (191) 1471 (169) 1545 (295) 1636 (232)
 Patient with extra‑
renal replacement 
therapy, admissions, 
(%)
1621 (8.4) 204 (4.8) 352 (7.1) 250 (7.8) 424 (10.3) 391 (13.3)
 Mean extra‑renal 
replacement 
therapy, mean 
hours/month (SD)
1370 (847) 763 (460) 1162 (717) 1037 (437) 1824 (883) 2091 (843)
Patients
 Number 18,286 3981 4607 3022 3901 2775
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were no significant differences between period D and E 
(p = 0.96 and p < 0.08). Hence, these results confirm the 
overall findings of the main analysis.
Comparison of CHG dressings
We sequentially introduced two types of CHG dressings 
for all catheters: CHG sponge over periods B and C and 
CHG gel dressings over periods D and E. During period 
D, CHG gel replaced CHG sponge in two of the five 
ICU units. We therefore also compared period C (CHG 
sponge on all catheters) with period E (CHG gel on all 
catheters) in Table 2. We observed a decrease of CABSI 
when CHG gel dressing (7 episodes) was used instead of 
CHG sponge dressing (18 episodes), translating into a 
reduction of incidence density rates to 0.23 episodes per 
1000 catheter-days (95% CI 0.11–0.48) in period E com-
pared with 0.69 (95% CI 0.43–1.09, p = 0.019) in period 
C. The p values for CRBSI and primary bacteremia were 
0.018 and 0.99, respectively (Table 2a). Period D was the 
time when both CHG sponge and CHG gel were used, 
providing another opportunity to compare the dressings 
(Table 2b). During period D, we observed nine infections 
(0.43 CABSI per 1000 catheter-days; 95% CI 0.23–0.83) 
with CHG sponge compared with two (0.13 CABSI per 
1000 catheter-days; 95% CI 0.03–0.50) with CHG gel. The 
concomitant comparison did not, however, reach statisti-
cal significance (p = 0.059, Table 2b).
Post‑study period
Data from January 2015 to December 2018 showed a 
CABSI rate of 0.32 (95% CI 018–0.49) episodes per 1000 
central venous catheter-days, suggesting that the pro-
gressive decrease we observed during the study was sus-
tained post-study (Fig. 2).
Adverse effect of CHG dressings
We evaluated skin tolerance during the introduction 
of Tegaderm™ CHG during period D. To this end, an 
independent dermatologist assessed all the observed 
skin reactions (Supplemental Fig.  3). From June 2011 
to January 2012, 26 skin reactions were recorded with 
Tegaderm™ CHG (5.5 episodes/1000 device-days) and 
CRBSI catheter-related bloodstream infection, CABSI catheter-associated bloodstream infection, i.e., CRBSI + primary bacteremia
*See supplemental Table 2
Table 1 (continued)
Period A B C D E
 Age, year (median, 
IQR)
63.7 (51.4–73.9) 62.6 (50.3–73.2) 63.6 (50.8–74.4) 65.0 (54.3–74.5) 64.3 (52.3–74.6) 65.2 (52.6–
74.5)
 Males, n (%) 12,025 (65.8) 2632 (66.1) 3040 (66.0) 1995 (66.0) 2536 (65.0) 1822 (65.7)
Patient comorbidities
 NYHA IV (%) 1864 (10.2) 396 (9.9) 554 (12.0) 348 (11.5) 335 (8.6) 231 (8.3)
 Chronic dialysis, n (%) 396 (2.2) 80 (2.0) 114 (2.5) 49 (1.6) 67 (1.7) 86 (3.1)
 Severe COPD, n (%) 1383 (7.6) 309 (7.8) 312 (6.8) 215 (7.1) 288 (7.4) 259 (9.3)
 Liver cirrhosis, n (%) 739 (4.0) 128 (3.2) 171 (3.7) 121 (4.0) 182 (4.7) 137 (4.9)
 Metastatic cancer, 
n (%)
2356 (12.9) 461 (11.6) 581 (12.6) 375 (12.4) 541 (13.9) 398 (14.3)
 Mc Cabe—within 
5 years, n (%)
5088 (27.8) 1078 (27.1) 1342 (29.1) 824 (27.3) 1021 (26.2) 823 (29.7)
 Mc Cabe—within 
1 year, n (%)
1741 (9.5) 290 (7.3) 415 (9.0) 265 (8.8) 458 (11.7) 313 (11.3)
Major critical illness
 Hemorrhagic shock, 
n (%)
657 (3.6) 130 (3.3) 100 (2.2) 112 (3.7) 166 (4.3) 149 (5.4)
 Cardiogenic shock, 
n (%)
726 (4.0) 166 (4.2) 157 (3.4) 126 (4.2) 136 (3.5) 141 (5.1)
 Septic shock, n (%) 1299 (7.1) 207 (5.2) 326 (7.1) 180 (6.0) 331 (8.5) 255 (9.2)
 Pneumonia, n (%) 2511 (13.7) 544 (13.7) 587 (12.7) 382 (12.6) 544 (13.9) 454 (16.4)
 Peritonitis, n (%) 408 (2.2) 87 (2.2) 114 (2.5) 58 (1.9) 81 (2.1) 68 (2.5)
Severity
 SAPS II median (IQR) 38 (27–49) 35 (25–45) 36 (26–47) 38 (29–49) 41 (30–53) 40 (28–51)
 ICU mortality, n (%) 1974 (10.8) 386 (9.7) 441 (9.6) 305 (10.1) 474 (12.2) 368 (13.3)
 Hospital post‑ICU 
mortality, n (%)
539 (2.9) 115 (2.9) 157 (3.4) 100 (3.3) 99 (2.5) 68 (2.5)
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5 with  Biopatch® (0.9 episodes/1000 device-days). They 
were all scored as allergic reactions. In March 2012, we 
introduced a newly designed Tegaderm™ CHG with 
improved evaporation capability, while the  Biopatch® 
did not change. From March 2012 to May 2013, two skin 
reactions were observed with Tegaderm™ CHG (0.3/1000 
device-days) and one with  Biopatch® (0.3/1000 device-
days). Of note, no CABSIs occurred in these patients.
Discussion
The stepwise introduction of two types of CHG dress-
ings over a 7-year period achieved a sharp and sustained 
reduction in all types of catheter-related infections, 
despite increased workload, catheter use and severity of 
illness.
For the first time, a real-world data study, consisting of 
prospective surveillance of 155,242 catheter-days, con-
firms that the addition of CHG dressings to existing cath-
eter bundles provides a significant decrease in the rate of 
catheter-related bloodstream infections in a real-world 
setting. Post-study surveillance data showed a persistent 
low rate of infections over an additional 4-year period.
CRBSI are considered the most preventable nosoco-
mial infection [4]. Over the last 2 decades, catheter bun-
dles, aiming at reducing contamination during insertion 
procedures and subsequent hub handling, resulted in 
a substantial decrease in CLABSI rates, down to values 
between one and two episodes per 1000 catheter-days [3, 
12, 14].
By adding an antimicrobial agent to control the bacte-
rial load at the insertion site, chlorhexidine dressings can 
further reduce the CLABSI rate. Timsit et al. conducted 
two milestone prospective randomized controlled trials 
on this topic. The first study [15] tested the same CHG 
sponge dressing we used in periods B, C and D. It evalu-
ated 1636 patients for a total of 28,931 catheter-days. 
Compared with standard dressings, the CHG sponge 
dressings achieved a decrease in catheter-related infec-
tions (defined as either catheter-related clinical sepsis 
without bloodstream infection or CRBSI) from 1.4 to 0.6 
episodes per 1000 catheter-days (hazard ratio: 0.39; 95% 
CI 0.17–0.93; p = 0.03). The second study [16] tested the 
same CHG gel dressing we used in periods D and E. It 
evaluated 1879 patients for a total of 34,339 catheter-
days. Compared with non-chlorhexidine dressings, the 
CHG gel dressings achieved a decrease in CRI (defined as 
in the previous study) from 2.1 to 0.7 episodes per 1000 
catheter-days (hazard ratio: 0.328; 95% CI 0.174–0.619; 
p = 0.0006) and a decrease in CRBSI from 1.3 to 0.5 epi-
sodes per 1000 catheter-days (hazard ratio: 0.402; 95% CI 
0.186–0.868; p = 0.02).
Our data not only confirm these results in a real-word 
setting, but also provide additional evidence to support 
the recommendation endorsed by the guidelines for the 
Table 2 Comparison of two types of CHG dressings
Infections (n) and incidence density rates of infections (episodes per 1000 catheter-days; 95% CI) by type of dressing
(a) Period C (sponge only) versus period E (gel only)
All Period C sponge only Period E gel only Period E vs. 
period C
Catheter‑day 56,477 26,128 30,349
CABSI 25 18 7
Incidence density rate of infection (95% CI) 0.44 (0.28–0.66) 0.69 (0.43–1.09) 0.23 (0.11–0.48) 0.019
CRBSI 14 11 3
Incidence density rate of infection (95% CI) 0.25 (0.14–0.42) 0.42 (0.23–0.76) 0.10 (0.03–0.31) 0.018
Primary bacteremia 11 7 4
Incidence density rate of infection (95% CI) 0.19 (0.10–0.35) 0.27 (0.13–0.56) 0.13 (0.05–0.35) 0.99
(b) CHG sponge vs. CHG gel (intervention 3, period D)
Period D only June 2011 to May 2013 All CHG sponge 18 beds CHG gel 14 beds Comparison 
of gel ver‑
sus sponge
Catheter‑day 36,689 20,807 15,882
CABSI 11 9 2
Incidence density rate of infection (95% CI) 0.30 (0.17–0.54) 0.43 (0.23–0.83) 0.13 (0.03–0.50) 0.059
CRBSI 6 4 2
Incidence density rate of infection (95% CI) 0.16 (0.07–0.36) 0.19 (0.07–0.51) 0.13 (0.03–0.50) 0.49
Primary bacteremia 5 5 0
Incidence density rate of infection (95% CI) 0.14 (0.06–0.33) 0.24 (0.10–0.58) Undefined < 0.001
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generalized use of CHG dressings in acutely ill patients 
[18, 19]. Comparing the initial period, during which the 
state-of-the-art bundle was in use, and the last period 
during which the CHG gel dressing was used for all 
patients and catheters, we observed a sixfold reduction in 
the CABSI rate, corresponding to 16 (95% CI 13.6–19.3) 
episodes avoided every year.
Moreover, the enhanced bundle impacted CRBSI and 
primary bacteremia similarly, independently of case mix 
variation. This suggests that primary bacteremia might 
be correlated with catheter infection in  situations such 
as ours where catheter tip cultures are not systematically 
performed.
Our study has several strengths. First, it is a large real-
world data study including > 18,000 patients and 160,000 
catheter-days over 9  years. This is comparable to the 
recent meta-analysis including nine studies with antisep-
tic dressings [17]. Second, the observation was done in a 
mixed tertiary ICU admission with severely critically ill 
patients, as assessed by high severity scores and work-
load required to manage them. The single-center design 
limits the external validity on one hand but ensures a 
higher degree of consistency of processes of care on the 
other. Third, the sustained decrease in infection rate was 
achieved despite a continuous increase in case mix sever-
ity over time. Finally, the recording of the data was per-
formed without changes in the setting of the surveillance, 
in the definitions of infections or in the staff in charge of 
catheter-bundle training and maintenance.
Our study also has several limitations. First, it is mono-
centric and without randomization and therefore does 
not qualify for a pragmatic trial. Hence, we cannot dis-
criminate between the relative impact of the ongoing 
bundle over time and the precise contribution of CHG 
dressings. However, data from the literature suggest 
that if catheter bundles have a sustainable effect, this 
seems to be limited to stabilization of the rate of infec-
tion rather than permitting a continuous further decrease 
over time [7, 8, 22, 23]. Second, the study design did not 
allow determining the effect of the generalization of alco-
holic 2% chlorhexidine for skin preparation introduced 
in period D. Third, although systematic education and 
continuous bedside teaching to comply with the catheter 
bundle were provided, we never formally assessed com-
pliance. Fourth, the absence of systematic catheter cul-
ture may result in an underestimation of the true rate of 
Fig. 2 Post‑study surveillance data (2015‑2018) of catheter‑associated bloodstream infections (CABSI). CABSI expressed as rate of infection by 
central venous catheter‑days. Period A: 2.31 (95% CI 1.61–3.0) CABSIs per 1000 central venous catheter‑days; period B: 1.15 (0.77–1.54); period C: 0.69 
(0.37–1.01); period D: 0.47 (0.19–0.75); period E: 0.38 (0.10–0.67); post‑study period: 0.34 (0.18–0.49)
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CRBSI. Episodes may have been scored as primary bacte-
remia and then included in CABSI already defined as the 
primary end point. Finally, the improved results might 
result not only from the use of chlorhexidine dressings 
on top of the bundle, but also from the creation of an 
environment and culture of quality improvement com-
mitment among staff, generated by the long-lasting chain 
of quality improvement initiatives, with breakthrough 
interventions, supported by educational tools and data 
feedback.
Our data suggest that CHG gel may be more effective 
than CHG sponge to prevent CABSI in adult patients 
requiring ICU management. Comparing periods C (CHG 
sponge on all catheters) and E (CHG gel on all catheters), 
the CABSI and CRBSI incidence density rates almost 
reached the significance level of 0.017 accounting for 
multiple comparisons (p = 0.019 and 0.018, respectively; 
see Table 2a). Due to the small numbers of infections, the 
power to detect a difference between those periods was 
only 77% and not the usual 80% targeted. For period D 
during which both dressings were used concomitantly 
and where the effect of the ongoing catheter bundle was 
identical, the difference did not reach significance either 
(two episodes, hazard ratio: 0.13; 95% CI 0.03–0.50, ver-
sus nine episodes, hazard ratio: 0.43; 95% CI 0.23–0.83, 
per 1000 catheter-days, p = 0.059). The absence of signifi-
cant difference may be due to low power to assess a sig-
nificant difference in this comparison (49%) or to random 
chance. A potential significant superiority of the gel could 
further improve infection control and decrease rates of 
CABSI. This hypothesis should however be addressed by 
a sufficiently powered prospective controlled study.
Calculation of cost-effectiveness was beyond the 
scope of the study. However, the stepwise implementa-
tion of the enhanced catheter bundle has changed the 
empirical management of patients developing sepsis 
of unknown origin. First, systematic catheter change 
(guidewire exchange or insertion at new sites) was no 
longer required, thus avoiding the risk associated with 
new catheterization. Second, for the same reason, van-
comycin was not systematically added in empirical anti-
biotic treatment of sepsis of unknown origin to treat an 
eventual CABSI, thus contributing to reducing antibiotic 
exposure. Finally, these changes in patient management 
combined with a sustained reduction in CABSI might 
have resulted in cost reduction as suggested by Maun-
oury et al. [5, 24].
We conclude that the addition of chlorhexidine dress-
ings to all CVC and arterial lines to an ongoing catheter 
bundle in all patients requiring ICU admission resulted 
in a sustained and probably cost-effective 11-year reduc-
tion of catheter-associated bloodstream infections.
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